Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest [Yahoo! Finance]
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? [Yahoo! Finance]
ArriVent BioPharma (AVBP) was upgraded by Truist Financial Corporation to "strong-buy".
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib [Seeking Alpha]
ArriVent BioPharma (AVBP) had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.